Positive results in clinical trials on Nubewax 14′ vaccine, BE Ltd

RSD-Hyderabad news: Biological E. Limited (BE) has reached a major milestone in the development of a vaccine targeted at preventing pneumococcal disease in young children. Nubewax 14; (BE-PCV-14) pneumococcal conjugate vaccine has shown very positive results in phase III clinical trials here, the company said on 30.04.2024. The results of these tests were published in the peer-reviewed journal ‘Vaccine’. The vaccine trials were conducted on 1290 infants aged 6 to 8 weeks in 15 locations across the country. One dose was given at 6-10 weeks infants and the results were analyzed. Biological E. Limited has revealed that the safety of this vaccine has been confirmed and its ability to prevent the disease has been demonstrated. Mahima Datla, MD, Biological E. Limited, explained that since it has been confirmed that this vaccine can be given to young children, we are close to releasing the vaccine.